Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Net Cash Flow rose 16450.02% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 19532.93%. This contributed to the annual value of -$20.2 million for FY2024, which is 8555.76% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Net Cash Flow stood at $8.0 million for Q3 2025, which was up 16450.02% from $11.7 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Net Cash Flow peaked at $173.2 million during Q4 2022, and registered a low of -$122.7 million during Q1 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$7.6 million (2022), whereas its average is $1.8 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Net Cash Flow in the last 5 years was 50891.19% (2023), contrasted with its biggest fall of 146170.1% (2023).
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Net Cash Flow stood at $121.5 million in 2021, then surged by 42.61% to $173.2 million in 2022, then tumbled by 93.97% to $10.4 million in 2023, then grew by 6.91% to $11.2 million in 2024, then decreased by 28.16% to $8.0 million in 2025.
  • Its Net Cash Flow stands at $8.0 million for Q3 2025, versus $11.7 million for Q2 2025 and -$11.0 million for Q1 2025.